A single-center, double-blind, placebo-controlled evaluation of lamotrigine in the treatment of obesity in adults

Journal of Clinical Psychiatry

Volumn 67, Issue 2, 2006, Pages 258-262

  Merideth, Charles H ^a  

^a Affiliated Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAT; GLYCOSYLATED HEMOGLOBIN; LAMOTRIGINE; LIPID; PLACEBO;

ADULT; ARTICLE; BODY FAT; BODY MASS; BODY WEIGHT; BRONCHITIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMMON COLD SYMPTOM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; INFLUENZA; LIPID BLOOD LEVEL; MALE; OBESITY; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; STATISTICAL SIGNIFICANCE; URTICARIA;

EID: 33644828519     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n0212     Document Type: Article

References (16)

1. National Institutes of Health. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. 1998. No. 98-4083. Available at: http://www.nhlbi.nih. gov/guidelines/obesity/ob_gdlns.pdf. Accessed November 15, 2005
2. Wadden TA, Berkowitz RI, Sarwer DB, et al. Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial. Arch Intern Med 2001;161:218-227
3. Glazer G. Long-term pharmacotherapy for obesity 2000: a review of efficacy and safety. Arch Intern Med 2001;161:1814-1824
4. Aronne LJ, Segal KR. Weight gain in the treatment of mood disorders. J Clin Psychiatry 2003;64(suppl 8):22-29
5. Nemeroff CB. Safety of available agents used to treat bipolar disorder: focus on weight gain. J Clin Psychiatry 2003;64:532-539
6. Devinsky O, Vuong A, Hammer A, et al. Stable weight during lamotrigine therapy: a review of 32 studies. Neurology 2000;54:973-975
7. Potter D, Edwards KR, Norton J. Sustained weight loss associated with 12-month topiramate therapy. Epilepsia 1997;38:97
8. Biton V, Mirza W, Montouris G, et al. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001;56:172-177
9. Jones MW. Topiramate: safety and tolerability. Can J Neurol Sci 1998; 25:S13-S15
10. McIntyre RS, Riccardelli R, Binder C, et al. Open-label adjunctive topiramate in the treatment of unstable bipolar disorder. Can J Psychiatry 2005;50:415-422
11. Bray GA, Hollander P, Klein S, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003;11:722-733
12. Bowden CL, Asnis GM, Ginsberg LD, et al. Safety and tolerability of lamotrigine for bipolar disorder. Drug Saf 2004;27:173-184
13. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(suppl 20):22-33
14. Kolotkin RL, Head S, Brookhart A. Construct validity of the Impact of Weight on Quality of Life Questionnaire. Obes Res 1997;5: 434-441
15. Lamictal [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2005
16. Brown ES, Nejtek VA, Perantie DC, et al. Lamotrigine in patients with bipolar disorder and cocaine dependence. J Clin Psychiatry 2003;64: 197-201